Work

Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity

Year: 2016

Type: review

Abstract: Since the 2002 Dusseldorf meeting, one new agent, Benlysta, has been approved by the US Food and Drug Administration for systemic lupus erythematosus. Experiences from the field in conducting trials of all the agents tested during this period have provided valuable practical insights. There has been incremental progress in defining the minimal clinically important difference (MCID) of key disease manifestations and the view is largely that of the health care providers and not that of the person suffering the disease. This basic methodological work on the MCID should improve the efficiency and the clinical relevance of future trials and their design.

Source: Arthritis Research & Therapy

DOI: 10.1186/s13075-015-0906-9

Authors: Chan-Bum Choi, Matthew H. Liang, Sang-Cheol Bae

Institutions: Brigham and Women's Hospital, VA Boston Healthcare System, VA New England Healthcare System, Hanyang University Seoul Hospital, Hanyang University Hospital for Rheumatic Disease

Language: English

Topic: Systemic Lupus Erythematosus Research

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,690